Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PAPPA encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). Additionally we are shipping PAPPA Antibodies (411) and PAPPA Kits (44) and many more products for this protein.
Showing 10 out of 21 products:
STC2 (show STC2 Proteins) is involved in regulating PAPP-A activity during the development of atherosclerosis
Study demonstrates proof-of-principle and provides feasibility for a novel therapeutic strategy to inhibit atherosclerotic plaque burden by selective targeting of PAPP-A.
stimulation of PAPP-A expression by intermittent PTH (show PTH Proteins) treatment contributes to PTH (show PTH Proteins) bone anabolism in mice
PAPP-A affects fascicle structure, thereby affecting tendon phenotype.
PAPP-A has a role in development of advanced plaque with necrotic cores and buried fibrous caps (show CAPS Proteins) in the brachiocephalic artery
these data indicate preferential impact of PAPP-A deficiency on visceral fat in the mouse that is associated with enhanced insulin receptor (show INSR Proteins) signaling
Studies show a conditional PAPP-A knockout (KO) model for efficacy of tamoxifen-induced floxed PAPP-A excision in various tissues and indicate a significant reduction of neointimal formation after unilateral carotid artery ligation.
absence of PAPP-A is associated with resistance to the development of indicators of diabetic nephropathy in mice
Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.
Data conclude that PAPP-A proteolytic activity is required for the lesion-promoting effect of PAPP-A and that its specificity must be directed against IGFBP-4 (show IGFBP4 Proteins).
data indicate that PAPP-A promotes TF expression in human endothelial cells and support the hypothesis that this proteinase, besides being involved in progression of atherosclerosis, does not represent an independent risk factor for adverse cardiovascular events, but it rather might play an "active" role in the pathophysiology of ACS as an effector molecule able to induce a pro-thrombotic phenotype in endothelial cells
assessed serum PAPP-A levels in COPD (show ARCN1 Proteins) and the associations with disease severity; elevated levels of PAPP-A were observed in patients with COPD (show ARCN1 Proteins)
Data suggest that stanniocalcin 1 (show STC1 Proteins) and 2 (STC1 (show STC1 Proteins), STC2 (show STC2 Proteins)) participate in inhibition of proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A) during folliculogenesis.
measurements of maternal serum PAPP-A concentration in the first trimester predict severe fetal growth restriction more effectively than they predict a birth weight below the 10th percentile among a Chinese population
Women with PAPP-A =10th percentile in the first trimester are more likely to have an small-for gestational age infant at all gestational ages. PAPP-A >/=90th percentile is protective against small for gestational age, and is associated with an increased risk of large for gestational age for infants born after 32 weeks gestation.
Data suggest that incidences of intrauterine growth restriction, pre-eclampsia, preterm birth, and fetal death are significantly greater in pregnant women with low serum levels of PAPP-A in first trimester (9-13 weeks of pregnancy) as compared to control pregnant women; study was conducted in India.
The first trimester maternal PAPP-A levels were decreased in the ICSI group compared with those in the controls, but not in IVF (show SCN5A Proteins) and embryo transfer groups.
miR (show MLXIP Proteins)-141 may play important roles in ox-LDL-induced abnormal proliferation of the vascular smooth muscle cells by targeting PAPPA.
Combined analysis of PAPP-A and free beta-hCG (show CGA Proteins) appears to be a potential candidate to predict early fetal loss.
study determined IGFR1 (show IGF1R Proteins) and PAPP-A expression both in follicles at different stages of development and in ovarian cysts; data indicate that animals with cystic ovarian disease (COD (show SNRPB Proteins)) have an altered regulation of the IGF system in the ovary and thus allow postulating IGFR1 (show IGF1R Proteins) expression and PAPP-A secretion as a modulator of IGF1 (show IGF1 Proteins) in cattle with COD (show SNRPB Proteins)
in preovulatory follicles, PAPP-A is responsible for IGF-dependent IGFBP-2 degradation
concluded that changes in granulosa cell PAPP-A mRNA levels do not occur during final preovulatory follicular development in cattle
This gene encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses.
IGF-dependent IGFBP-4 protease
, insulin-like growth factor-dependent IGF-binding protein 4 protease
, aspecific BCL2 ARE-binding protein 2
, differentially placenta 1 expressed protein
, insulin-like growth factor-dependent IGF binding protein-4 protease
, pregnacy-associated plasma protein A
, PAPPA-like protein
, pregnancy-associated plasma protein A-like protein
, cleaves insulin-like binding protein-4 (IGFBP-4)